-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$3.331485.71% Upside
NexImmune, Inc. Frequently Asked Questions
-
What analysts cover NexImmune, Inc.?
NexImmune, Inc. has been rated by research analysts at Barclays, Raymond James, BTIG in the past 90 days.